{
    "2018-02-05": [
        [
            {
                "time": "",
                "original_text": "推荐评级医药行业周报：进入年报期 关注业绩的确定性和持续性",
                "features": {
                    "keywords": [
                        "医药行业",
                        "年报期",
                        "业绩",
                        "确定性",
                        "持续性"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "买入评级美年健康(002044)深度报告：高成长的体检龙头 流量价值逐步凸显",
                "features": {
                    "keywords": [
                        "美年健康",
                        "高成长",
                        "体检",
                        "流量价值"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗健康"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "强于大市评级医药生物行业投资策略：优选“业绩拐点+估值修复”品种 巧避”雷区”",
                "features": {
                    "keywords": [
                        "医药生物",
                        "投资策略",
                        "业绩拐点",
                        "估值修复",
                        "雷区"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药行业：创新和终端格局重构两条主线选股",
                "features": {
                    "keywords": [
                        "医药行业",
                        "创新",
                        "终端格局",
                        "重构",
                        "选股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "51股获券商买入评级 启明星辰目标涨幅达55.34%",
                "features": {
                    "keywords": [
                        "券商买入评级",
                        "启明星辰",
                        "目标涨幅"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}